The report also covers products from therapy areas such as Oncology, Central Nervous System, and Genetic Disorders which include the indications Multiple Myeloma (Kahler Disease), Melanoma, Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, Charcot-Marie-Tooth Disease Type II, and Polycystic Kidney Disease . It also reviews key players involved in Histone Deacetylase 6 targeted therapeutics development with respective active and dormant or discontinued products.
The Histone Deacetylase 6 pipeline targets constitutes close to 51 molecules. Out of which, approximately 42 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 5, 9, 1, 29, and 7 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 6, and 3 molecule.
Histone Deacetylase 6 overview
Histone deacetylase 6 is an enzyme encoded by the HDAC6 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. It is involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. It plays a key role in the degradation of misfolded proteins. It acts as an adapter that recognizes polyubiquitinated misfolded proteins and target them to the aggresome, facilitating their clearance by autophagy.
For a complete picture of Histone Deacetylase 6’s drug pipeline, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.